article thumbnail

Scrub-a-Dub-Dub: FTC is Cleansing the Orange Book of Device Patents

FDA Law Blog: Biosimilars

Koblitz — As we have noted for the last year or so, the FTC has been on a mission to clean up the Orange Book by removing what it deems to be “improper” patents. FTC, deep in its foray into the Orange Book, filed an Amicus Brief in the case arguing that the patents do not claim any FDA-approved drug. And on X (R.I.P.

FDA 116
article thumbnail

FTC takes aim at pharma patent tactics used to block generics

BioPharma Drive: Drug Pricing

The antitrust regulator is examining what it describes as abuse of the FDA “Orange Book” — another step in its scrutiny of pharma business practices.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FTC Continues to Rage Against Device Patent Listings in the Orange Book

FDA Law Blog: Biosimilars

Koblitz — The FTC appears to be on a mission to cleanse the Orange Book of patents it deems improperly listed. For the second time in recent years, the FTC has filed an Amicus Brief explaining exactly which patents should not be in the Orange Book. Because a “drug product” is defined by regulation as a “Finished dosage form.

FDA 59
article thumbnail

To List or Not to List; That is the Question – The FTC Signals the Potential for Greater Scrutiny of Patent Information Submissions to FDA

FDA Law Blog: Biosimilars

Karst — Listing patent information in the Orange Book is a matter of judgment, but that judgment call is about to get a bit more scrutiny. Last week, the FTC held a Listening Session about the listing of patents in the Orange Book, which concluded with a unanimous vote to issue a Policy Statement.

FDA 105
article thumbnail

The Issue with Reissue: PTE Edition

FDA Law Blog: Biosimilars

Koblitz Integral to the careful balance Congress struck when passing the Hatch-Waxman Amendments, the patent term extension (PTE) is intended to restore patent life that was consumed during regulatory review of an FDA-regulated product.

article thumbnail

Risk Management Data Strategy – Insights from an Inquisitive Overseer

Perficient: Drug Development

Banks have silos, these silos have been created due to mergers, regulations, entities, risk types, chinese walls, data protection, land laws or sometimes just technological challenges over time. With Fundamental Review of the Trading Book (FRTB) the focus has been very clearly realigned to data processes in organizations.

article thumbnail

Zigs & Zags – The Opposite of a Great Idea Can Also be a Great Idea

Perficient: Drug Development

Several books have been written on the concept, and many more refer to it when discussing differentiation and disruption within marketing and product development. The book, Zero to One by Peter Thiel, covers advice for startups and those entrepreneurial-minded folks who want to build the future. We did amazing work together.

Marketing 116